Vemurafenib, Cetuximab, and Irinotecan Hydrochloride in Treating Patients With Solid Tumors That Are Metastatic or That Cannot Be Removed by Surgery

NCT01787500 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

47

Enrollment

OTHER

Sponsor class

Conditions

BRAF NP_004324.2:p.V600X
KRAS wt Allele
Metastatic Malignant Solid Neoplasm
Stage IV Colorectal Cancer AJCC v7
Stage IVA Colorectal Cancer AJCC v7
Stage IVB Colorectal Cancer AJCC v7
Unresectable Solid Neoplasm

Interventions

BIOLOGICAL: Cetuximab
DRUG: Irinotecan Hydrochloride
OTHER: Laboratory Biomarker Analysis
OTHER: Pharmacological Study
DRUG: Vemurafenib

Sponsor

M.D. Anderson Cancer Center

Collaborators

[object Object]
[object Object]